Hypo-Stream Ltd is an emerging pharmaceutical company based in Cambridge, UK, with late-stage development therapeutic assets.
The company is founder-led by a group of experienced clinicians, world-class scientists and seasoned pharmaceutical industry professionals
Find out more
Treating acute respiratory distress syndrome (ARDS) and COVID19
ARDS occurs when the body’s inflammatory response to a lung infection triggers wider septic shock, as well as severe pneumonia. It can have any number of causes and has a very high mortality rate due to lack of effective treatment.
Treating life-threatening inflammatory response
Acute inflammatory diseases come on fast and can be life-threatening. From severe reactions to insect bites, to acute asthma attacks, acute dermatitis flares, acute respiratory distress syndrome (ARDS and Sepsis) and acute inflammatory response to burns, gunshot wounds and surgery, conditions in the acute inflammatory group can need a different approach to effective treatment.
Addressing the surging problem of antimicrobial resistance
There is a growing problem with the prevalence of antibiotic-resistance pathogens, with a wide range of current and potential consequences that include increased mortality from infections and a reduction in non-emergency surgical procedures.
Improving survival and healing outcomes in severe burns
Typical survival rates for patients with burns of over 20% total body surface area is extremely poor. For those who do survive, multiple surgeries are often necessary, and scarring is a life-long problem. Long stays in intensive care are the norm, with a huge cost for the healthcare provider and long recovery times for patients.
